Solid Biosciences Inc.

About Solid Biosciences Inc.

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, and catecholaminergic polymorphic ventricular tachycardia. Founded by individuals directly impacted by Duchenne, their mission is to improve the daily lives of patients with devastating rare diseases through innovative science, technology, and patient care.

Products & Services

Gene Therapy for Duchenne Muscular Dystrophy:Developing gene therapy candidates targeting Duchenne muscular dystrophy, a rare neuromuscular disease.

Gene Therapy for Friedreich's Ataxia:Advancing treatments for Friedreich's ataxia, a rare genetic disorder affecting the nervous system and heart.

Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT):Focused on gene therapies for CPVT, a rare cardiac condition.

Gene Therapies for Dilated Cardiomyopathies (TNNT2 and BAG3-mediated):Developing therapies for specific genetic cardiac diseases causing dilated cardiomyopathy.

Genetic Regulators and Delivery Technologies:Creating innovative libraries of genetic regulators and enabling technologies to enhance gene therapy delivery across industries.

Specialties

Gene Therapy Neuromuscular Diseases Cardiac Diseases Duchenne Muscular Dystrophy Friedreich's Ataxia Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Genetic Regulators Delivery Platform Technologies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 200000000 MR: - FA: approximately $200.0 million FAN: 200000000	D: 2025-02-18 FD: 2025-02-18	11 investors
2	RT: Private Placement T: - FT: Private Placement	A: 108900000 MR: - FA: $108.9 million FAN: 108900000	D: 2024-01-08 FD: 2024-01-08	9 investors

Underwritten Offering Latest

2025-02-18

$200.0M

11 investors (Pro only)

Private Placement 2024-01-08

$108.9M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

I

Ilan Ganot

Co-Founder and Strategic Advisor to the CEO

A

Annie Ganot

Co-Founder

A

Andrey Zarur

Former Chairman of the Board

M

Matt Arnold

Founder

G

Gilad Hayeem

Co-Founder

I

Ian F. Smith

Chairman of the Board

View 16 more team members with Pro

Unlock Full Team Directory

Recent News